Florian Bassermann

List of Publications by Year
in descending order

55	2,205	394421	233421
papers	citations	19 h-index	45 g-index

57	57	57	4831
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Autophagy in mesenchymal progenitors protects mice against bone marrow failure after severe intermittent stress. Blood, 2022, 139, 690-703.	1.4	8
2	A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer. Bioorganic Chemistry, 2022, 119, 105505.	4.1	13
3	MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma. Blood Advances, 2022, 6, 515-520.	5.2	5
4	Concomitantly discovered visceral artery aneurysms do rarely grow during cancer therapy. Clinical Anatomy, 2022, 35, 296-304.	2.7	3
5	Genetic alterations of the SUMO isopeptidase SENP6 drive lymphomagenesis and genetic instability in diffuse large B-cell lymphoma. Nature Communications, 2022, 13, 281.	12.8	18
6	Initial evaluation of [18F]-FACBC for PET imaging of multiple myeloma. EJNMMI Research, 2022, 12, 4.	2.5	4
7	Circulating Tumor DNA Profiling of a Diffuse Large B Cell Lymphoma Patient with Secondary Acute Myeloid Leukemia. Cancers, 2022, 14, 1371.	3.7	3
8	Conditioning with fludarabine and treosulfan compared to FLAMSA-RIC in allogeneic stem cell transplantation for myeloid malignancies: a retrospective single-center analysis. Annals of Hematology, 2022, 101, 1311-1319.	1.8	1
9	Implementation of CRISPR/Cas9 Genome Editing to Generate Murine Lung Cancer Models That Depict the Mutational Landscape of Human Disease. Frontiers in Cell and Developmental Biology, 2021, 9, 641618.	3.7	25
10	ABO subgroup incompatibility with severe hemolysis after consecutive allogeneic stem cell transplantations. EJHaem, 2021, 2, 280-284.	1.0	0
11	Bone marrow stromal cells from MDS and AML patients show increased adipogenic potential with reduced Delta-like-1 expression. Scientific Reports, 2021, 11, 5944.	3.3	20
12	The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma. Molecular Cell, 2021, 81, 1170-1186.e10.	9.7	39
13	Tumor cellâ€intrinsic RIGâ€I signaling governs synergistic effects of immunogenic cancer therapies and checkpoint inhibitors in mice. European Journal of Immunology, 2021, 51, 1531-1534.	2.9	7
14	MLKL promotes cellular differentiation in myeloid leukemia by facilitating the release of G-CSF. Cell Death and Differentiation, 2021, 28, 3235-3250.	11.2	9
15	CHIP and hips: clonal hematopoiesis is common in patients undergoing hip arthroplasty and is associated with autoimmune disease. Blood, 2021, 138, 1727-1732.	1.4	58
16	Functional analysis of peripheral and intratumoral neoantigen-specific TCRs identified in a patient with melanoma. , 2021, 9, e002754.		7
17	Cyclophosphamide plus etoposide is a safe and effective mobilization regimen in patients with multiple myeloma. Transfusion and Apheresis Science, 2021, 60, 103197.	1.0	2
18	Comprehensive characterization of central BCL-2 family members in aberrant eosinophils and their impact on therapeutic strategies. Journal of Cancer Research and Clinical Oncology, 2021, 148, 331.	2.5	2

#	Article	IF	Citations
19	Multiple Myeloma: Molecular Pathogenesis and Disease Evolution. Oncology Research and Treatment, 2021, 44, 672-681.	1.2	25
20	Combination Treatment of Venetoclax and Hypomethylating Agents (HMA) or Low-Dose Cytarabine (LDAC) for Patients with Acute Myeloid Leukemia (AML) - Real-World Data from Two German Academic Centers. Blood, 2021, 138, 1257-1257.	1.4	1
21	IFN-Gamma Producing Regulatory T Cells Counterbalance T Cell-Mediated Injury to the Intestinal Stem Cell Compartment in Mice and Humans. Blood, 2021, 138, 89-89.	1.4	1
22	Characterization of Somatic Mosaicism and Mutational Profiling of Clonal Hematopoiesis Compared to MDS and sAML Depicts Diversities of Clonal Evolution. Blood, 2021, 138, 3278-3278.	1.4	1
23	Microbial-Derived Metabolites Induce Epithelial Recovery Via the Sting Pathway in Mice and Men and Protect from Graft-Versus-Host Disease. Blood, 2021, 138, 87-87.	1.4	0
24	Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany. Haematologica, 2020, 105, 2872-2878.	3.5	40
25	MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeutically. Nature Communications, 2020, 11, 4527.	12.8	32
26	Antagonistic activities of CDC14B and CDK1 on USP9X regulate WT1-dependent mitotic transcription and survival. Nature Communications, 2020, 11, 1268.	12.8	22
27	Prognostic value of indoleamine 2,3 dioxygenase in patients with higherâ€risk myelodysplastic syndromes treated with azacytidine. British Journal of Haematology, 2020, 190, 361-370.	2.5	9
28	CXCR4-Targeted PET Imaging of Central Nervous System B-Cell Lymphoma. Journal of Nuclear Medicine, 2020, 61, 1765-1771.	5.0	34
29	Bortezomib, lenalidomide, and dexamethasone (VRD) is superior to lenalidomide, adriamycin, and dexamethasone (RAD) prior to risk-adapted transplant in newly diagnosed myeloma.. Journal of Clinical Oncology, 2020, 38, 8521-8521.	1.6	2
30	Cross Talk Networks of Mammalian Target of Rapamycin Signaling With the Ubiquitin Proteasome System and Their Clinical Implications in Multiple Myeloma. International Review of Cell and Molecular Biology, 2019, 343, 219-297.	3.2	16
31	Type I interferon signaling before hematopoietic stem cell transplantation lowers donor T cell activation via reduced allogenicity of recipient cells. Scientific Reports, 2019, 9, 14955.	3.3	9
32	RIG-I activation is critical for responsiveness to checkpoint blockade. Science Immunology, 2019, 4, .	11.9	80
33	Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose. Experimental Hematology and Oncology, 2019, 8, 9.	5.0	36
34	Type I Interferon Signaling before Hematopoietic Stem Cell Transplantation Lowers Donor T Cell Activation Via Reduced Allogenicity of Recipient Cells. Blood, 2019, 134, 4431-4431.	1.4	0
35	CXCR4-Targeted Positron Emission Tomography Imaging of Central Nervous System B-Cell Lymphoma. Blood, 2019, 134, 2900-2900.	1.4	1
36	RIG-I Activation Is Critical for Responsiveness to Checkpoint Blockade. Blood, 2019, 134, 624-624.	1.4	1

#	Article	IF	Citations
37	Patterns of Renal Recovery and Toxicity with Novel Agent-Based Induction Triplets in Newly Diagnosed Multiple Myeloma - an Analysis of Two Prospective Studies By the German DSMM Myeloma Study Group. Blood, 2019, 134, 1840-1840.	1.4	0
38	<scp>FBXL</scp> 13 directs the proteolysis of <scp>CEP</scp> 192 to regulate centrosome homeostasis and cell migration. EMBO Reports, 2018, 19, .	4.5	18
39	Direct modulation of the bone marrow mesenchymal stromal cell compartment by azacitidine enhances healthy hematopoiesis. Blood Advances, 2018, 2, 3447-3461.	5.2	31
40	Lenalidomide, Adriamycin and Dexamethasone (RAD) Versus Bortezomib, Lenalidomide and Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) - Post-Induction Response and MRD Results By Flow Cytometry and NGS from a Phase 3 Randomized Controlled Clinical Trial (RCT). Blood, 2018, 132, 1979-1979.	1.4	1
41	The target landscape of clinical kinase drugs. Science, 2017, 358, .	12.6	609
42	Lenalidomide, doxorubicin hydrochloride and dexamethasone versus bortezomib, lenalidomide, and dexamethasone prior to scheduled stem cell transplant in newly diagnosed myeloma.. Journal of Clinical Oncology, 2017, 35, 8001-8001.	1.6	1
43	Cereblon and Redox in Plasma Cells. Blood, 2017, 130, SCI-9-SCI-9.	1.4	0
44	USP9X stabilizes XIAP to regulate mitotic cell death and chemoresistance in aggressive Bâ€cell lymphoma. EMBO Molecular Medicine, 2016, 8, 851-862.	6.9	50
45	Immunomodulatory drugs disrupt the cereblonâ€“CD147â€“MCT1 axis to exert antitumor activity and teratogenicity. Nature Medicine, 2016, 22, 735-743.	30.7	145
46	BCL3 Reduces the Sterile Inflammatory Response in Pancreatic and Biliary Tissues. Gastroenterology, 2016, 150, 499-512.e20.	1.3	30
47	Results from two phase III studies of bortezomib (BTZ) consolidation vs observation (OBS) post-transplant in patients (pts) with newly diagnosed multiple myeloma (NDMM).. Journal of Clinical Oncology, 2015, 33, 8511-8511.	1.6	9
48	Î±-Radioimmunotherapy with 213Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma. Oncotarget, 2015, 6, 4692-4703.	1.8	42
49	Disruption of the PRKCDâ€“FBXO25â€“HAX-1 axis attenuates the apoptotic response and drives lymphomagenesis. Nature Medicine, 2014, 20, 1401-1409.	30.7	50
50	The ubiquitin proteasome system â€" Implications for cell cycle control and the targeted treatment of cancer. Biochimica Et Biophysica Acta - Molecular Cell Research, 2014, 1843, 150-162.	4.1	214
51	SCFFbxo9 and CK2 direct the cellular response to growth factor withdrawal via Tel2/Tti1 degradation and promote survival in multiple myeloma. Nature Cell Biology, 2013, 15, 72-81.	10.3	76
52	NIPA Phosphorylation and Inactivation at G2/M Is Mediated by ERK2.. Blood, 2009, 114, 2513-2513.	1.4	0
53	The Cdc14B-Cdh1-Plk1 Axis Controls the G2 DNA-Damage-Response Checkpoint. Cell, 2008, 134, 256-267.	28.9	365
54	Multisite Phosphorylation of Nuclear Interaction Partner of ALK (NIPA) at G2/M Involves Cyclin B1/Cdk1. Journal of Biological Chemistry, 2007, 282, 15965-15972.	3.4	28

#	Article	IF	Citations
55	Multisite Phosphorylation of NIPA at G2/M.. Blood, 2007, 110, 3348-3348.	1.4	0